Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Depreciation and Depletion: 2011-2024

Historic Depreciation and Depletion for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $14.9 million.

  • Ptc Therapeutics' Depreciation and Depletion fell 34.53% to -$24.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $6.6 million, marking a year-over-year increase of 40.43%. This contributed to the annual value of $14.9 million for FY2024, which is 7.19% up from last year.
  • Ptc Therapeutics' Depreciation and Depletion amounted to $14.9 million in FY2024, which was up 7.19% from $13.9 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Depreciation and Depletion ranged from a high of $14.9 million in FY2024 and a low of $6.6 million during FY2020.
  • Moreover, its 3-year median value for Depreciation and Depletion was $13.9 million (2023), whereas its average is $13.7 million.
  • Data for Ptc Therapeutics' Depreciation and Depletion shows a peak YoY skyrocketed of 42.42% (in 2021) over the last 5 years.
  • Ptc Therapeutics' Depreciation and Depletion (Yearly) stood at $6.6 million in 2020, then skyrocketed by 42.42% to $9.4 million in 2021, then spiked by 30.85% to $12.3 million in 2022, then increased by 13.01% to $13.9 million in 2023, then grew by 7.19% to $14.9 million in 2024.